ADVFN - Advanced Financial Network.
HOME» NASDAQ » G » GILD Stock Price » GILD Stock News

Gilead Sciences Share News

 Gilead Sciences (mm) Stock Price
GILD Stock Price
 Gilead Sciences (mm) Stock Chart
GILD Stock Chart
 Gilead Sciences (mm) Stock News
GILD Stock News
 Gilead Sciences (mm) Company Information
GILD Company Information
 Gilead Sciences (mm) Stock Trades
GILD Stock Trades

Bristol-Myers Discontinues Development of Hepatitis C Drug

By Nathalie Tadena Bristol-Myers Squibb Co. (BMY) said Thursday it has discontinued the development of a drug intended to treat the liver disease hepatitis C in the interest of patient safety, after a patient died and others were hospitalized. Bristol-Myers earlier this month voluntarily suspended a Phase 2 study of BMS-986094, which was formerly known as INX-189, a nucleotide polymerase inhibitor, or "nuke." The initial case of heart failure, which was the basis for halting the study, subsequently resulted in death, the company said Thursday. Bristol-Myers said it is working with the U.S. Food and Drug Administration and clinical study investigators to conduct ongoing and close follow-ups of all the study's patients. To date, nine patients have been hospitalized, including the initial patient, and two remain hospitalized. The company said the cause of these unexpected events, which involve heart and kidney toxicity, hasn't been definitively established. Bristol-Myers decision to halt the study earlier this month raised questions about the experimental drug's potential and the $2.5 billion price tag Bristol paid earlier this year to buy the company that developed it. The suspension was considered a significant setback for the drug maker--already grappling with weak sales of its Plavix anticlotting drug that lost patent protection in May--in the race to develop new hepatitis C treatments. Bristol-Myers as well as other companies such as Gilead Sciences Inc. (GILD) and Abbott Laboratories (ABT) has been looking to bring the first all-oral hepatitis C regimen to market, hoping to tap what is expected to be a multibillion-dollar market for such a therapy. To strengthen its hepatitis C position, Bristol-Myers in February shelled out $2.5 billion to buy Inhibitex Inc. at a whopping 163% premium. Bristol was lured primarily by Inhibitex's nuke for hepatitis C, though it did acquire other potential treatments for infectious disease in the deal. Treatments for hepatitis C are considered lucrative because the disease is prevalent in large sections of the global population. The virus, which can be transmitted sexually or through use of shared needles and at tattoo parlors, affects some 170 million people world-wide. Separately, Synergy Pharmaceuticals Inc. (SGYP) said it has agreed to acquire the assets related to shingles treatment FV-100 from Bristol-Myers. FV-100 was developed by Inhibitex. Shares were up by 10 cents to $32.25 after hours. The stock has fallen 8.8% since the start of the year. -Write to Nathalie Tadena at Subscribe to WSJ:

Stock News for Gilead Sciences (GILD)
11/25/201514:23:49Statement of Changes in Beneficial Ownership (4)
11/25/201514:22:53Statement of Changes in Beneficial Ownership (4)
11/24/201517:00:00Gilead Sciences to Present at Two Upcoming Investor Conferences...
11/24/201510:24:00Europäische Kommission erteilt Marktzulassung für das Einzeltablettenregime G...
11/24/201508:38:03Healthcare's Greatest Dividend Stocks
11/24/201506:00:00La Commission européenne accorde une autorisation de mise sur...
11/23/201521:46:00La Commissione Europea rilascia l'autorizzazione alla commercializzazione...
11/23/201510:01:03Can Merck & Co. Take Down Gilead Sciences?
11/23/201506:35:00European Commission Grants Marketing Authorization for Gilead’s S...
11/21/201509:04:08Gilead Sciences Inc. Has Plenty of Room to Run in Hepatitis C
11/20/201510:07:58Confidential Treatment Order (ct Order)
11/18/201512:33:49Statement of Changes in Beneficial Ownership (4)
11/18/201511:45:02This Just In: Upgrades and Downgrades
11/17/201511:53:00Le Zydelig® de Gilead, combiné à la bendamustine et au rituximab, dé...
11/17/201509:42:033 Biotech Stocks You Don't Have to Babysit
11/17/201509:42:033 Biotech Stocks You Don't Have to Babysit
11/17/201509:42:033 Biotech Stocks You Don't Have to Babysit
11/16/201520:51:00Zydelig® di Gilead in combinazione con bendamustina e rituximab...
11/16/201515:44:00Zydelig® von Gilead in Verbindung mit Bendamustin und Rituximab...
11/16/201509:00:00Gilead’s Zydelig® Combined with Bendamustine & Rituximab Shows Su...

Gilead Sciences and other NASDAQ stock quotes are delayed by at least 20 minutes.
All other stock price and quote data is delayed by at least 15 minutes unless otherwise stated. By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Contact Us | Copyright 1999-2007 ADVFN PLC. | Privacy Policy | Investment Warning | Data accreditations | Investor Relations